European Journal of Cancer - McMaster Experts

publication venue for

Psychosocial outcomes following contralateral prophylactic mastectomy in women with unilateral, nonhereditary breast cancer 2020
The role of chemotherapy and radiotherapy in localized extraskeletal osteosarcoma 2020
Viral sensitizers potential infection of cancer cells via NF-kappaB 2019
Expression of monoamine oxidase a is correlated with three-dimensional tumorsphere-formation by human breast tumor cells lines 2018
A Canadian Cancer Trials Group phase IB study of durvalumab with or without tremelimumab + standard platinum-doublet chemotherapy in patients with advanced, incurable solid malignancies (IND.226) 2016
Dose ranging study of monalizumab (IPH2201) in patients with gynecologic malignancies: A trial of the Canadian Cancer Trials Group (CCTG): IND221 2016
Tumour matrix stiffness regulates metastasis by promoting cancer cell interactions with the endothelium 2016
2200 TOPGEAR: A randomized phase M/MI trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer. Interim results from an international, intergroup trial of the AGITG/TROG/NCIC CTG/EORTC 2015
2508 Three-arm phase II randomized trial of docetaxel monotherapy or combined with ramucirumab or icrucumab in second-line locally advanced or metastatic urothelial carcinoma 2015
3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses 2015
3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC) 2015
205 Metformin to modulate AMP-kinase and enhance chemotherapy and radiotherapy in non-small cell lung cancer 2014
508 A phase Ib trial of AMG386 and temsirolimus in patients with advanced sold tumors (PJC-008/NCI#9041) 2014
A cost-minimization analysis of NCIC Clinical Trials Group LY.12: A phase III study of gemcitabine, clexamethasone, and cisplatin (GDP) compared to dexamethasone, cytarabine, and cisplatin (DHAP) for patients with relapsed or refractory aggressive histology non-Hodgkin's lymphoma 2013
Difficulties in meeting accrual and obtaining adequate follow up in palliative trials: Results from an intergroup randomized trial of single vs multiple fractions (Fx) for re-irradiation (RE-RT) of painful bone metastases (PBM): NCIC CTG SC.20 2013
Genomic testing in cancer (GTC): Patient knowledge, attitudes and expectations 2013
Homecare utilization and costs in stage IV lung cancer: a Canadian public payer experience 2013
Prognostic risk stratification of men with advanced penile squamous cell cancer (PSCC) receiving first-line systemic therapy 2013
Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial 2013
Simultaneous cone beam CT scans captured during prostate radiotherapy; image quality and the effect of arc delivery time 2013
607 NCIC CTG IND.196: Phase I Study of Foretinib (GSK1363089) and Erlotinib in Patients with Advanced Pretreated NSCLC 2012
239 The Cancer-associated K351N Mutation Affects the Ubiquitination and the Translocation to Mitochondria of p53 Protein 2012
Fulvestrant Alone or with Concomitant Anastrozole Vs Exemestane Following Progression On Non-steroidal Aromatase Inhibitor - First Results of the SoFEa Trial (CRUKE/03/021 & CRUK/09/007) (ISRCTN44195747) 2012
Impact of Survivorship Care Plans (SCP) On Adherence to Guidelines, Health Service Measures, and Patient-reported Outcomes (PRO): Extended Results of a Multicenter Randomized Clinical Trial (RCT) with Breast Cancer Survivors 2012
1314 POSTER Quality of Reporting of Modern Randomized Controlled Trials in Oncology 2011
3001 POSTER DISCUSSION Ultra-low-molecular-weight Heparin (ULMWH) Semuloparin for Prevention of Venous Thromboembolism (VTE) in Cancer Patients Receiving Chemotherapy: Consistent Beneficial Effect Across Cancer Stage and Location Subgroups 2011
406 INVITED Stereotactic Radiotherapy for Liver Metastases 2011
6088 POSTER KRAS and EGFR MicroRNAs Regulation and Cetuximab/Panitumumab Sensitivity in Metastatic Colorectal Cancer Patients 2011
Quality of Life in the ICON7 GCIG Phase III Randomised Clinical Trial 2011
Introduction 2006
Final results of a phase I study of the Raf-1 kinase inhibitor BAY 43-9006 in patients with advanced refractory solid tumours 2002
Phase II study of OSI-774 in patients with metastatic colorectal cancer 2002
The NCIC CTG MA.14 experience with the gallbladder toxicity of octreotide pamoate (oncolar) in a postmenopausal patient population undergoing adjuvant treatment for stage 1-3 breast cancer 2002
Assessment of alternative and complimentary medicines and devices in cancer patients attending a multi-disciplinary cancer centre 1999
NCIC CTG IND 113: two phase I dose escalation pharmacokinetic (PK) studies of BAY 12-9566 (BAY) in combination with either doxorubicin (DOX) or modulated 5-fluorouracil (FU) 1999
Results of a randomized phase II study of two schedules of bryostatin-I in patients with malignant melanoma: experience with the multivariate stopping rule 1999
p53 and WAF1 expression in epithelial ovarian cancer: Prognostic and predictive implications 1998
S35 CEF versus CMF in premenopausal women — Recent update 1998
Economic evaluation of chemotherapy with Mitoxantrone plus Prednisone for symptomatic hormone resistant prostate cancer based on a Canadian randomised trial with palliative endpoints 1997
Opportunities to reduce the cost of care for breast cancer (BC) in Canada 1997
Phase II trial of the multi-targeted antifolate LY231514 (MTA) as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC) 1997
Concurrent daily chemotherapy with hyperfractionated thoracic irradiation in stage IIIA&B NSCLC 1995
Preventing nausea and vomiting during days 2-7 following high dose cisplatin chemotherapy (HDCP) 1995
The health economics of lung cancer and an estimate of the cost effectiveness of single agent gemcitabine in stage IV NSCLC 1995
A model for the study of treatment response in human normal and tumour cells 1987
Guidance for discussants of randomized cancer trials at major meetings.. 220:115357. 2025
Modified Delphi consensus on interventions for radiation dermatitis in breast cancer: A Canadian expert perspective. 200:45-45. 2024
Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12. 180:108-116. 2023
Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Primary results from PALOMA-4. 175:236-245. 2022
Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. 171:124-132. 2022
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma. 163:55-65. 2022
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. 160:1-11. 2022
Clinical practice guideline for the prevention of oral and oropharyngeal mucositis in pediatric cancer and hematopoietic stem cell transplant patients: 2021 update. 154:92-101. 2021
Health care utilisation and costs associated with different treatment protocols for newly diagnosed childhood acute lymphoblastic leukaemia: A population-based study in Ontario, Canada. 151:126-135. 2021
A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. 142:132-140. 2021
187 Poster Psychosocial outcomes following contralateral prophylactic mastectomy in women with unilateral, nonhereditary breast cancer. 138:s44-s45. 2020
Recommendations from the European Commission Initiative on Breast Cancer on multigene tests to guide the use of adjuvant chemotherapy in patients who have hormone receptor positive, HER-2 negative, lymph node negative or up to 3 lymph nodes positive invasive breast cancer. 138:S12-S13. 2020
Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. 135:203-210. 2020
Current state of quality of life and patient-reported outcomes research. 121:55-63. 2019
The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. 108:69-77. 2019
Patient-reported symptoms after breast cancer diagnosis and treatment: A retrospective cohort study. 101:1-11. 2018
C-statistic: A brief explanation of its construction, interpretation and limitations. 90:130-132. 2018
Corrigendum to “Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles” [Eur J Cancer 70 (2017) 62–74]. 83:335-335. 2017
Exercise training improves physical function and fitness in long-term paediatric brain tumour survivors treated with cranial irradiation. 80:63-72. 2017
Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6). 72:192-199. 2017
Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles. 70:62-74. 2017
Serotonergic antagonists target breast tumor-initiating cells in mouse models of human breast cancer. 69:S83-S83. 2016
The influence of gene expression profiling on decisional conflict in decision making for early-stage breast cancer chemotherapy. 61:85-93. 2016
Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer. 59:65-78. 2016
Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome. 51:2501-2507. 2015
1525 Rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV): Efficacy and safety over multiple cycles of highly or moderately emetogenic chemotherapy. 51:S212-S213. 2015
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. 51:1405-1414. 2015
Influence of censoring on conclusions of trials for women with metastatic breast cancer. 51:721-724. 2015
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. 50:706-712. 2014
Clear cell renal cell carcinoma induces fibroblast-mediated production of stromal periostin. 49:3537-3546. 2013
Symptom clusters in a population-based ambulatory cancer cohort validated using bootstrap methods. 48:3073-3081. 2012
357 Impact of Survivorship Care Plans (SCP) On Adherence to Guidelines, Health Service Measures, and Patient-reported Outcomes (PRO): Extended Results of a Multicenter Randomized Clinical Trial (RCT) with Breast Cancer Survivors. 48:S147-S147. 2012
An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. 48:324-332. 2012
Central nervous system atypical teratoid rhabdoid tumours: The Canadian Paediatric Brain Tumour Consortium experience. 48:353-359. 2012
Nutritional status at diagnosis is related to clinical outcomes in children and adolescents with cancer: A perspective from Central America. 48:243-252. 2012
Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: A phase II trial. 48:37-45. 2012
Early stopping rules in oncology: Considerations for clinicians. 47:2381-2386. 2011
6604 POSTER Updated Survival and Genomic Analysis of a Phase II Trial of Temsirolimus in Advanced Neuroendocrine Carcinomas. 47:S473-S473. 2011
The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium. 47:1373-1379. 2011
Randomised controlled trials in oncology closed early for benefit: Trends in methodology, results, and interpretation. 47:854-863. 2011
The unclear zone in phase II clinical trials. 46:2408-2413. 2010
Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. 46:1573-1579. 2010
Health-related quality of life of long-term childhood cancer survivors: A population-based study from the Childhood Cancer Registry of Piedmont, Italy. 43:2545-2552. 2007
Long term survivors of childhood cancer: Cure and care. 43:1778-1780. 2007
Guidelines on the standards for the training of specialised health professionals dealing with breast cancer. 43:660-675. 2007
Osteonecrosis in children and adolescents with cancer – An adverse effect of systemic therapy. 43:683-689. 2007
Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. 42:1875-1880. 2006
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?. 42:548-556. 2006
Use of paediatric versus adult oncology treatment centres by adolescents 15–19 years old: the Canadian Childhood Cancer Surveillance and Control Program. 41:404-410. 2005
Economic evaluation of treatments for cancer in childhood. 40:1335-1345. 2004
Canada's Population Health Model (POHEM). 37:1797-1804. 2001
The adolescent with cancer. 37:1523-1527. 2001
A randomized trial of high-dose chemotherapy (HDCT) with autologous peripheral blood stem cell support (asct) compared to standard chemo therapy (ct) in women with metastatic breast cancer: a National Cancer Institute of Canada (NCIC) clinical trials group study. 37:S285-S285. 2001
Health-related quality of life of patients with malignant pleural mesothelioma treated with pemetrexed disodium. 37:s282. 2001
NCIC CTG IND.122: a phase I/II pharmacokinetics (PK) and pharmacodynamic (PD) study of zd1839 (iressa ‘TM’). Final phase I results and preliminary phase II results of ZD1839 (750 mg/day) in patients (pts) with colorectal cancer. 37:S289-S289. 2001
Physical interaction with yes-associated protein enhances p73 transcriptional activity. 37:S279-S279. 2001
Randomised phase II study of BMS-275291 versus placebo in patients (pts) with stage IIIb or IV non small cell lung cancer (NSCLC) receiving paclitaxel + carboplatin (PC): National Cancer Institute of Canada clinical trials group (NCIC CTG) br.18. 37:S19-S20. 2001
The p53 family: What implications in human carcinogenesis?. 37:S138-S139. 2001
IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. 37:478-485. 2001
Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer. 36:2329-2334. 2000
Response from D. Feeny, et al.. 36:1460-1461. 2000
Estimates of the lifetime costs of breast cancer treatment in Canada. 36:724-735. 2000
NCIC CTG IND102: a phase II study of the oral platinum compound BMS-182751 in patients with advanced and or recurrent squamous cell carcinoma of the cervix. 35:S235-S235. 1999
Æ-941, an inhibitor of angiogenesis: rationale for development in combination with induction chemotherapy/radiotherapy in patients with non-small-cell lung cancer (nsclc). 35:S250-S250. 1999
Applicability of the Health Utilities Index to a Population of Childhood Survivors of Central Nervous System Tumours in the U.K.. 35:256-261. 1999
Health-related quality of life in survivors of tumours of the central nervous system in childhood—a preference-based approach to measurement in a cross-sectional study1Presented in part to the meetings of the International Society of Pediatric Oncology (SIOP) in Paris, September 1994 and Montevideo, October 1995.1. 35:248-255. 1999
Detection of SYT–SSX1/2 fusion transcripts by reverse transcriptase–polymerase chain reaction (RT–PCR) is a valuable diagnostic tool in synovial sarcoma. 34:2087-2093. 1998
The prognostic role of gender in survival of adult cancer patients. 34:2271-2278. 1998
The prognostic role of gender in survival of adult cancer patients. EUROCARE Working Group.. 34:2271-2278. 1998
Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: report of a workshop. 34:1317-1333. 1998
A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer. 34:1008-1014. 1998
Osteopenia in children surviving brain tumours. 34:873-877. 1998
The evidence for tamoxifen and chemotherapy as treatment for metastatic melanoma. 34:31-36. 1998
PP15. Methods for conducting economic analysis of the long-term management of breast cancer: Description of two current Canadian studies. 33:S19-S20. 1997
Phase II trial of the multi-targeted antifolate LY231514 (MTA) as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC). 33:S231-S231. 1997
Direct osteolysis induced by metastatic murine melanoma cells: Role of matrix metalloproteinases. 33:918-925. 1997
A survey of telomerase activity in human cancer. 33:787-791. 1997
Letter to the Editor: Comments on Health-related Quality of Life of Adults Surviving Malignancies in Childhood, Apajasalo et al., Eur J Cancer, 32A, No. 8, pp. 1354-1358, 1996. 33:506-507. 1997
The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer. 32:2249-2255. 1996
1057 The health economics of lung cancer and an estimate of the cost effectiveness of single agent gemcitabine in stage IV NSCLC. 31:S221-S221. 1995
1100 Concurrent daily chemotherapy with hyperfractionated thoracic irradiation in stage IIIA & B NSCLC. 31:S229-S229. 1995
1204 Preventing nausea and vomiting during days 2–7 following high dose cisplatin chemotherapy (HDCP). 31:S251-S251. 1995
Radiology in the detection and prevention of colorectal cancer. 31:1121-1126. 1995
VP-16, ifosfamide and cisplatin (VIP) for extensive small cell lung cancer. 30:299-303. 1994
A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. 29:37-43. 1993
Chemotherapy induced amenorrhoea in a randomised trial of adjuvant chemotherapy duration in breast cancer. 29:21-23. 1993
Dexamethasone (DEX) improves the efficacy of granisetron (GRAN) in the first 24 hours following high dose cisplatin (HDCP) chemotherapy. 29:S208-S208. 1993
Clinical significance of natural killer cell cytotoxicity: Need for proper data analysis in the design of clinical studies. 21:1287-1293. 1985

European Journal of Cancer Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)